Blueprint Medicines Corporation EPS Ratio 2011-2025 | BPMC

EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.

The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares^[1]

EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.

A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.

EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.

Annual EPS Ratio Blueprint Medicines Corporation

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-1.07	-8.37	-9.35	-11	5.76	-7.27	-5.39	-3.92	-2.64	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
5.76	-11	-4.81

Quarterly EPS Ratio Blueprint Medicines Corporation

2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
0.01	-	-0.89	-0.8	1.45	-	-2.2	-2.19	-2.15	-	-2.23	-2.68	-1.79	-	-2	-1.86	-1.72	-	11.5	-2.28	-2.11	-1.35	-1.93	-2.04	-1.98	-1.83	-1.66	-0.62	-1.29	-1.23	-0.96	-0.86	-0.84	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
11.5	-2.68	-1.02

References

Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.

EPS Ratio of other stocks in the Biotechnology industry

Issuer	EPS Ratio	Price	% 24h	Market Cap	Country
Cellectis S.A. CLLS	-2.55	$ 4.3	12.57 %	$ 116 M	France
Graybug Vision GRAY	-7.66	$ 0.44	-11.23 %	$ 9.65 M	USA
AgeX Therapeutics AGE	-13.7	$ 11.3	-10.17 %	$ 12.2 K	-
Galera Therapeutics GRTX	-0.34	$ 0.14	-32.59 %	$ 7.61 M	USA
Cyclerion Therapeutics CYCN	-1.21	$ 2.52	-1.18 %	$ 6.35 M	USA
AnPac Bio-Medical Science Co., Ltd. ANPC	-2.66	$ 4.37	-1.58 %	$ 28.1 M	China
Caladrius Biosciences CLBS	-2.4	$ 0.43	-16.75 %	$ 25.8 M	USA
Sorrento Therapeutics SRNE	-1.45	$ 0.27	-29.58 %	$ 126 M	USA
BeiGene, Ltd. BGNE	-0.47	$ 184.71	0.49 %	$ 251 B	Cayman-islands
Midatech Pharma plc MTP	-31	$ 0.29	-18.52 %	$ 27.3 M	Britain
Aeterna Zentaris AEZS	-0.07	$ 5.72	5.93 %	$ 314 M	Canada
ContraFect Corporation CFRX	-125	$ 1.47	-5.16 %	$ 5.39 M	USA
Orchard Therapeutics plc ORTX	-1.18	$ 4.93	1.02 %	$ 90.8 M	Britain
Advaxis ADXS	-7.99	$ 0.31	-9.65 %	$ 45.9 M	USA
La Jolla Pharmaceutical Company LJPC	0.72	$ 6.2	-	$ 154 M	USA
Zymeworks ZYME	-4.11	$ 6.42	-	$ 404 M	Canada
Checkmate Pharmaceuticals CMPI	-2.84	$ 10.5	-	$ 231 M	USA
BioDelivery Sciences International BDSI	0.85	$ 2.58	-4.8 %	$ 255 M	USA
Zosano Pharma Corporation ZSAN	-0.27	$ 0.56	7.23 %	$ 2.72 M	USA
Ayala Pharmaceuticals AYLA	-2.46	$ 0.5	-	$ 7.46 M	Israel
Generation Bio Co. GBIO	-1.96	$ 6.33	1.61 %	$ 408 M	USA
Kiromic BioPharma KRBP	-64.4	$ 3.15	6.61 %	$ 3.08 M	USA
Albireo Pharma ALBO	-1.77	$ 44.15	-0.23 %	$ 916 M	USA
Stealth BioTherapeutics Corp MITO	-0.08	$ 0.32	-	$ 23.9 M	USA
Kaleido Biosciences KLDO	-2.16	$ 0.29	-3.69 %	$ 12.4 M	USA
Entasis Therapeutics Holdings ETTX	-1.09	$ 2.19	-	$ 105 M	USA
Heron Therapeutics HRTX	-0.09	$ 1.35	2.27 %	$ 206 M	USA
ImmuCell Corporation ICCC	-0.26	$ 6.59	2.17 %	$ 53.8 M	USA
Humanigen HGEN	-0.79	$ 0.04	-81.12 %	$ 4.28 M	USA
Aptinyx APTX	-0.96	$ 0.06	-39.0 %	$ 4.57 M	USA
Tyme Technologies TYME	-0.22	$ 0.31	8.07 %	$ 54 M	USA
Keros Therapeutics KROS	-5	$ 15.96	1.98 %	$ 598 M	USA
Forward Pharma A/S FWP	-0.02	$ 2.64	-0.75 %	$ 18.7 M	Danmark
Krystal Biotech KRYS	3.12	$ 187.18	2.27 %	$ 5.35 B	USA
Kymera Therapeutics KYMR	-2.98	$ 56.29	-1.11 %	$ 4.22 B	USA
Applied Genetic Technologies Corporation AGTC	-0.36	$ 0.39	-	$ 26.5 M	USA
Celyad Oncology SA CYAD	-1.7	$ 0.47	-	$ 12.5 M	Belgium
Brickell Biotech BBI	-1.06	$ 2.11	-5.38 %	$ 6.06 M	USA
Genocea Biosciences GNCA	-0.48	$ 0.05	-15.0 %	$ 3.04 M	USA
Codiak BioSciences CDAK	-1.7	$ 0.06	-55.98 %	$ 2.15 M	USA
Concert Pharmaceuticals CNCE	-2.33	$ 8.37	-	$ 401 M	USA
AIkido Pharma AIKI	-2.38	$ 3.17	1.93 %	$ 17.4 M	USA
Forma Therapeutics Holdings FMTX	-3.65	$ 20.01	-	$ 958 M	USA
Arena Pharmaceuticals ARNA	-10.1	$ 49.55	-6.81 %	$ 3.04 B	USA
Sierra Oncology SRRA	-7.14	$ 54.89	-0.05 %	$ 1.34 B	Canada